Hepatitis C Virus (HCV)

5

Review clinical trials related to Hepatitis C Virus (HCV). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System

The goal of this observational study is to develop, implement, and evaluate a machine learning algorithm-based Hepatitis C Emergency Department (HepC-EnD) screening tool for use in emergency departments (EDs) to identify patients at high risk of hepatitis C virus (HCV) infection. HepC-EnD will be integrated into the University of Florida Health electronic health record (EHR) system as a best practice alert (BPA) pop-up for ED providers, notifying them of patients at high risk for HCV infection and recommending both HCV and human immunodeficiency virus (HIV) screening. Investigators aim to enhance the screening and diagnosis of individuals who may otherwise remain undiagnosed and untreated. The implementation outcomes (e.g., usability) and effectiveness outcomes (e.g., HCV screening and diagnosis rates) of HepC-EnD targeted screening will be compared with universal screening (FOCUS) and conventional physician-initiated screening programs in EDs.

Participants needed: 6,466
Trial details
Age: 18-79Biological sex: AllType: ObservationalSponsor: University of FloridaUpdated: Apr 29, 2026Locations: 3
Eligibility criteria

18-79 years of age

< 18 years of age [+1]

Status: Recruiting

Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.

Participants needed: 2,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: AbbVieUpdated: Apr 16, 2026Locations: 2
Eligibility criteria

Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P). [+2]

Treated with DAAs other than G/P. [+3]

Status: Recruiting

California MEPS Hub

The California Hub for HIV/SUD Prevention Research with Reentry Populations addresses the question: "Can the evidence-based MEPS intervention be adapted and implemented at a range of organizations to effectively serve a wider range of clients?" The Mobile Enhanced Prevention Support (MEPS) intervention was originally implemented in Los Angeles County and was proven successful in promoting biomedical HIV prevention (PrEP) uptake and preventative screenings in people who used drugs who recently left incarceration. MEPS is an evidence-based intervention for people with substance use disorders (SUD) that incorporates a client-centered planning session, including trained peer mentors, service utilization incentives, and a mobile application (GeoPass). The study includes a randomized controlled trial (RCT) across three community partners located in Riverside and Alameda Counties. At least 300 people will be enrolled in these three counties; the first 200 will be randomized to either receive the intervention or usual care, with the final 100 all receiving the intervention. The primary implementation outcome for the study involves using an implementation science framework and assessment tools to examine MEPS's implementation. Key outcomes include how well the implementation strategies used support intervention enrollment and retention, integration with existing services in each partnering community agency, and perceived intervention acceptability, feasibility, appropriateness, and maintenance at 6- and 12-months. The primary effectiveness outcome for the study is an increase in HIV testing, PrEP uptake and adherence, and SUD service utilization at 6 months and 12 months in the MEPS compared to the usual care group. Secondary effectiveness outcomes include frequency of service use for SUDs, hepatitis C virus testing, and linkage to care for those who test positive for HIV or hepatitis C.

Participants needed: 318
Trial details
Age: 18-59Biological sex: MaleType: InterventionalSponsor: University of California, Los AngelesUpdated: Apr 3, 2026Locations: 3
Eligibility criteria

Assigned male at birth [+11]

Does not have a smart phone and is not willing to obtain one [+2]

Status: Not yet recruiting

MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo

Performance study to evaluate the clinical performance of the In-Vitro Diagnostic Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from pregnant women attending antenatal care (ANC) services in the Democratic Republic of the Congo. This study aligns with the WHO 2022-2030 strategy for the integrated elimination of mother-to-child transmission of HIV, HBV, HCV, and syphilis.

Participants needed: 7,500
Trial details
Biological sex: FemaleType: ObservationalSponsor: Gardiens de ViesUpdated: Feb 5, 2026Duration: 12 Months
Eligibility criteria

Being pregnant, regardless of age or stage of pregnancy (prenatal period); [+6]

Women in labor or who refuse to give their consent.

Status: Recruiting

Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons

This study is focused on improving the implementation of Prison Needle Exchange Programs (PNEPs) in Canadian federal prisons, with the goal of increasing the uptake of these programs among people who inject drugs in prison. The study is being conducted in nine federal prisons, including five women's prisons, where a higher proportion of incarcerated individuals report a history of injection drug use. This study aims to improve PNEP adoption and sustainability by identifying barriers and facilitators and implementing evidence-based strategies to enhance program engagement.

Participants needed: 548
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: McGill University Health Centre/Research Institute of the McGill University Health CentreUpdated: Dec 29, 2025Locations: 9
Eligibility criteria

All people incarcerated at a study site during the intervention period